Biotech firm Surrozen 2025 revenue drops to zero, net loss widens

Surrozen

23/03/2026 20:15

Corrects headline to say revenue dropped sharply, not 'to zero'; third Overview bullet to clarify the payment is yet to be received

Overview

U.S. biotech firm reported 2025 revenue fell sharply as collaboration revenue dropped to zero

Net loss widened significantly, driven by higher R&D costs and large non-cash charges

Company to receive $5 mln milestone payment from Boehringer Ingelheim; strengthened leadership team in 2025

Result Drivers

R&D SPENDING - Higher manufacturing, lab and consulting costs for ophthalmology programs drove increased R&D expenses, partially offset by lower clinical costs after discontinuing SZN-043

NON-CASH FINANCIAL CHARGES - Large non-cash losses from execution and revaluation of tranche liability related to the 2025 PIPE weighed on results

REVENUE DECLINE - End of collaboration and license revenue and termination of research service agreement with TCGFB led to lower revenue

Company press release: ID:nGNX7mlXbm

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY EPS
-$32.37
FY Net Income
-$242.03 mln
FY Operating Expenses
$45.57 mln
FY Operating Income
-$42.09 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

Wall Street's median 12-month price target for Surrozen Inc is $41.00, about 63% above its March 20 closing price of $25.15

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)